© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
September 16, 2020
The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.
July 31, 2020
A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.
May 13, 2020
The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.
April 28, 2020
J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.